Armata Gains FDA Fast Track for AP-SA02 with Rolling BLA, Targets H2 2026 Phase 3
Armata Pharmaceuticals secured Fast Track designation for AP-SA02, its IV multi-phage therapy treating MSSA and MRSA complicated bacteremia, granting rolling BLA review, frequent FDA engagement and Accelerated Approval eligibility. It is backed by positive Phase 1b/2a diSArm results and $26.2 million DoD funding and targets Phase 3 initiation in H2 2026.
1. FDA Fast Track Designation
Armata Pharmaceuticals announced FDA Fast Track designation for AP-SA02, its intravenously administered multi-phage therapy for complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA. The designation provides rolling Biologic License Application review, more frequent FDA interactions and eligibility for Accelerated Approval.
2. Clinical Progress and Phase 3 Plans
AP-SA02 advanced through a Phase 1b/2a diSArm study demonstrating safety, tolerability and efficacy in combination with standard antibiotics. The company plans to initiate a Phase 3 superiority trial in the second half of 2026 to confirm clinical benefit in complicated SAB.
3. DoD Funding and Phage Platform
The diSArm study received $26.2 million from the Department of Defense, supporting development under MTEC and NMRC management. Armata leverages its proprietary phage platform and in-house cGMP manufacturing to advance a pipeline targeting antibiotic-resistant infections.